Tekrarlayan ve kronik giardiasisli kedilerde fekal mikrobiyota transplantasyonu: Hedefe yönelik sağaltım

Yıl 2025, Cilt: 6 Sayı: 1, 1 - 7, 30.06.2025

Kerem Ural

https://doi.org/10.58833/bozokvetsci.1634745

Öz

Giardiasis hem insanlar hem de hayvanlar için önemli ölçüde sağlık açısından tehlikeli bir sorun teşkil eder. Zoonotik Giardia türlerine ev sahipliği yapma riski bulunan kedi giardiasisi için sınırlı tedavi seçenekleri vardır. Mevcut çalışma, kedilerde tekrarlayan ve kronik giardiasis hastalarına dışkı mikrobiyotası nakli (fmt) ile olası doğal ve tam bir tedavi sağlamayı amaçlamaktadır. Bu amaçla, G. duodenalis dışkı antijenleri (immünokromatografik), dışkı kisti/trofozoitleri (mikroskopik olarak flotasyon yoluyla) ve polimeraz zincir reaksiyonu ile gelişmiş tanısal fayda tüm çalışma boyunca mevcut kabul edilmiştir. Bu çalışma 2014-2024 yılları arasında 10 yıllık dönemi kapsamakta olup, giardiasisli kedilerde fekal mikrobiyota transplantasyonunun (fmt) etkinliğini saptanması amaçlanmıştır. Çalışmaya dahil edilen 11 kedide ilişkili tanısal testlerle kronikleşen giardiasis tanısı konuldu. Usülüne uygun fmt olgu bazında 1-3 kez uygulandıç Kist skorları sağaltım öncesi 2-4 arasında değişirken (4 olguda en yüksek kist skoru olan 4 puan tespit edildi], fmt ile sağaltım sonrası mukayeseli değerlendirmede 0 ile 2 arasında [en yüksek kist skoruna sahip 4 olgundan 3’ünde 1, 1inde 0 olarak) saptandı. Onbir olgunun 7’sinde fmt sonrası kist skorları 0 idi. Çalışma başlangıcında kist sayımlarına ilişkin skorlamalarda ortanca değer (3.0) ile fmt sonrası ortanca değer (1.0) arası istatsitiksel farklılığın (p=0.005) bulunması sağaltım başarısı ile ilişkilendirilebilinir.

Anahtar Kelimeler

giardiasis , fekal mikrobiyota transplantasyonu , kedi , kronik

Fecal microbiota transplantation in cats with recurrent and chronic giardiasis: targeted therapy

Öz

Giardiasis poses a significant health risk for both humans and animals. There are limited treatment options for feline giardiasis, which has the risk of harboring zoonotic Giardia species. The present study aims to provide a possible natural and complete treatment for recurrent and chronic giardiasis patients in cats with fecal microbiota transplantation (fmt). For this purpose, improved diagnostic utility with G. duodenalis fecal antigens (immunochromatographic), fecal cysts/trophozoites (microscopically by flotation) and polymerase chain reaction was assumed to be present throughout the study. This study covers a 10-year period between 2014 and 2024 and aims to determine the efficacy of fecal microbiota transplantation (fmt) in cats with giardiasis. Chronic giardiasis was diagnosed in 11 cats included in the study with relevant diagnostic tests. Appropriate fmt was applied 1-3 times on a case-by-case basis. While cyst scores varied between 2-4 before treatment (the highest cyst score was 4 in 4 cases), in the comparative evaluation after treatment with fmt, they were between 0 and 2 [3 out of 4 cases with the highest cyst score were 1 and 1 was 0]. Cyst scores after fmt were 0 in 7 out of 11 cases. The statistical difference (p=0.005) between the median value (3.0) and the median value (1.0) after fmt in the scores regarding cyst counts at the beginning of the study can be associated with the success of treatment.

Anahtar Kelimeler

cat , chronic , giardiasis , fecal microbiata transplantation

Kaynakça

• 1. Robertson LJ, Hanevik K, Escobedo AA, Mørch K, Langeland N. Giardiazis–why do the symptoms sometimes never stop?. Trends in Parasitology 2010; 26 (2): 75-82.
• 2. Chon SK, Kim NS. Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitology Research 2005; 97: 445-51.
• 3. Scorza AV, Radecki SV, Lappin MR. Efficacy of a combination of febantel, pyrantel, and praziquantel for the treatment of kittens experimentally infected with Giardia species. Journal of Feline Medicine and Surgery 2006; 8: 7-13.
• 4. Ural K, Erdoğan H, Adak Hİ, Ateş DS, Kahraman D. Ataksik kedilerde fekal mikrobiyota transplantasyonu. Veterinary Journal of Mehmet Akif Ersoy University 2019; 4(1) :34-36.
• 5. Robertson LJ, Hermansen L, Gjerde BK, Strand E, Alvsvag JO, Langeland N. Application of genotyping during an extensive outbreak of waterborne giardiazis in Bergen, Norway, during autumn and winter 2004. Applied and Environmental Microbiology 2006; 72(3): 2212-7.
• 6. Roxström-Lindquist K, Palm D, Reiner D, Ringqvist E, Svärd SG. Giardia immunity–an update. Trends in Parasitology 2006; 22(1): 26-31.
• 7. Alıç Ural D, Ayan A, Aysul N, Balıkçı C, Ural K. Secnidazol treatment to improve milk yield in sheep with giardiazis. Atatürk University Veterinary Science Journal 2014; 9(2): 74-82.
• 8. Alıç Ural D, Erdoğan H, Toplu S, Ayan A. Oğlaklarda Giardiazis kontrolüne yönelik oral klinoptilolit uygulaması. Kocatepe Veterinary Journal 2017; 10(3): 158-63.
• 9. Ural K, Aysul N, Voyvoda H, Ulutaş B, Aldemir OS, Eren H. Single dose of secnidazole treatment against naturally occurring Giardia duodenalis infection in Sakiz lambs. Revista MVZ Córdoba 2014; 19(1): 4023-32. 10. Faubert GM. The immune response to Giardia. Parasitology Today 1996; 12: 140-5.
• 11. Istre GR, Dunlop TS, Gaspard GB, Hopkins RS. Waterborne giardiazis at a mountain resort: evidence for acquired immunity. American Journal of Public Health 1984; 74(6): 602-4.
• 12. Barr SC. Enteric protozoal infections. In: Greene CE, editor. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders; 2006. p. 736-42.
• 13. Janeczko S, Griffin B. Giardia infection in cats. Compendium on Continuing Education for the Practicing Veterinarian 2010; 32(8): E4.
• 14. Uchôa FFDM, Sudré AP, Macieira DDB, Almosny NRP. The influence of serial fecal sampling on the diagnosis of giardiazis in humans, dogs, and cats. Revista do Instituto de Medicina Tropical de São Paulo 2017; 59: e61.
• 15. Smith PD, Gillin FD, Spira WM, Nash TE. Chronic giardiazis: studies on drug sensitivity, toxin production, and host immune response. Gastroenterology 1982; 83(4): 797-803.
• 16. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clinical Infectious Diseases 2008; 46(10): 1547-54.
• 17. Khanna R, Nain CK, Mehta S, Vinayak VK. Depressed humoral immune responses to surface antigens of Giardia lamblia in persistent giardiazis. Pediatric Infectious Disease Journal 1988; 7(7): 492-7.
• 18. Hanevik K, Hausken T, Morken MH, Strand EA, Mørch K, Coll P, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. Journal of Infection 2007; 55(6): 524-30.
• 19. Mørch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic characterisation of parasites in refractory giardiazis after an outbreak in Norway. Journal of Infection 2008; 56(4): 268-73.
• 20. Boucraut-Baralon and ABCD colleagues. GUIDELINE for Giardiazis. [Internet]. 2013. Available from: https://www.abcdcatsvets.org/guideline-for-giardiazis/?pdf=5262.
• 21. Di Prisco MC, Hagel I, Lynch NR, Jimenez JC, Rojas R, Gil M, et al. Association between giardiazis and allergy. Annals of Allergy, Asthma & Immunology 1998; 81(3): 261-5.
• 22. Buret AG. Pathophysiology of enteric infections with Giardia duodenalis. Parasite 2008; 15: 261-5.
• 23. Scott KGE, Yu LC, Buret AG. Role of CD8+ and CD4+ T lymphocytes in jejunal mucosal injury during murine giardiazis. Infection and Immunity 2004; 72(6): 3536-42.
• 24. Tomkins AM, Wright SG, Drasar BS, James WPT. Bacterial colonization of jejunal mucosa in giardiazis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1978; 72(1): 33-6.
• 25. Morken MH, Nysaeter G, Strand EA, Hausken T, Berstad A. Lactulose breath test results in patients with persistent abdominal symptoms following Giardia lamblia infection. Scandinavian Journal of Gastroenterology 2008; 43(2): 141-5.
• 26. Farthing MJ. Giardiazis. Gastroenterology Clinics of North America 1996; 25: 493-515.
• 27. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clinical Microbiology Reviews 2001; 14: 150-64.
• 28. Lalle M, Hanevik K. Treatment-refractory giardiazis: challenges and solutions. Infection and Drug Resistance 2018; 1921-33.
• 29. Gutiérrez JM, Aldasoro E, Requena A, Comin AM, Pinazo MJ, Bardají A, et al. Refractory giardiazis in Spanish travellers. Travel Medicine and Infectious Disease 2013; 11(2): 126-9.
• 30. Nabarro LEB, Lever RA, Armstrong M, Chiodini PL. Increased incidence of nitroimidazole-refractory giardiazis at the Hospital for Tropical Diseases, London: 2008-2013. Clinical Microbiology and Infection 2015; 21(8): 791-6.
• 31. Requena-Méndez A, Goñi P, Rubio E, Pou D, Fumadó V, Lóbez S, et al. The use of quinacrine in nitroimidazole-resistant Giardia duodenalis: an old drug for an emerging problem. Journal of Infectious Diseases 2017; 215(6): 946-53.
• 32. Leitsch D. Drug resistance in the microaerophilic parasite Giardia lamblia. Current Tropical Medicine Reports 2015; 2: 128-35.
• 33. Tejman-Yarden N, Millman M, Lauwaet T, Davids BJ, Gillin FD, Dunn L, et al. Impaired parasite attachment as fitness cost of metronidazole resistance in Giardia lamblia. Antimicrobial Agents and Chemotherapy 2011; 55(10): 4643-51.
• 34. Emery SJ, Baker L, Ansell BR, Mirzaei M, Haynes PA, McConville MJ, et al. Differential protein expression and post-translational modifications in metronidazole-resistant Giardia duodenalis. Gigascience 2018; 7(4): giy024.
• 35. Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology 2019; 146(9): 1167-78.
• 36. Müller J, Ley S, Felger I, Hemphill A, Müller N. Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. Journal of Antimicrobial Chemotherapy 2008; 62(1): 72-82.
• 37. Nash TE, Ohl CA, Thomas E, Subramanian G, Keiser P, Moore TA. Treatment of patients with refractory giardiasis. Clinical Infectious Diseases. 2001;33(1):22-8.
• 38. Halliez MC, Buret AG. Extra-intestinal and long-term consequences of Giardia duodenalis infections. World Journal of Gastroenterology 2013; 19(47): 8974.
• 39. Beatty JK, Akierman SV, Motta JP, Muise S, Workentine ML, Harrison JJ, et al. Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms. International Journal of Parasitology 2017; 47(6): 311-26.
• 40. Barash NR, Maloney JG, Singer SM, Dawson SC. Giardia alters commensal microbial diversity throughout the murine gut. Infection and Immunity 2017; 85(6): 10-1128.
• 41. Pavanelli MF, Colli CM, Gomes ML, Góis MB, de Melo GDAN, de Almeida Araújo EJ, et al. Comparative study of effects of assemblages AII and BIV of Giardia duodenalis on mucosa and microbiota of the small intestine in mice. Biomedicine & Pharmacotherapy 2018; 101: 563-71.
• 42. Vitetta L, Saltzman ET, Nikov T, Ibrahim I, Hall S. Modulating the gut micro-environment in the treatment of intestinal parasites. Journal of Clinical Medicine 2016; 5(11): 102.
• 43. Benyacoub J, Perez PF, Rochat F, Saudan KY, Reuteler G, et al. Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice. Journal of Nutrition 2005; 135(5): 1171-6.
• 44. Shukla G, Devi P, Sehgal R. Effect of Lactobacillus casei as a probiotic on modulation of giardiasis. Digestive Diseases and Sciences 2008; 53: 2671-9.
• 45. Shukla G, Kaur H, Sharma L. Comparative therapeutic effect of probiotic Lactobacillus casei alone and in conjunction with antiprotozoal drugs in murine giardiasis. Parasitology Research 2013; 112: 2143-9.
• 46. Besirbellioglu BA, Ulcay A, Can M, Erdem H, Tanyuksel M, Avci IY, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scandinavian Journal of Infectious Diseases 2006; 38(6-7): 479-81.
• 47. Amer EI, Mossallam SF, Mahrous H. Therapeutic enhancement of newly derived bacteriocins against Giardia lamblia. Experimental Parasitology 2014; 146: 52-63.
• 48. Allain T, Chaouch S, Thomas M, Travers MA, Valle I, et al. Bile salt hydrolase activities: a novel target to screen anti-Giardia lactobacilli?. Frontiers in Microbiology 2018; 9: 89.
• 49. Travers MA, Sow C, Zirah S, Deregnaucourt C, Chaouch S, Queiroz RM, et al. Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic Lactobacillus johnsonii La1 inhibit Giardia duodenalis in vitro growth. Frontiers in Microbiology 2016; 7: 1453.
• 50. Partida-Rodríguez O, Brown EM, Woodward SE, Cirstea M, Reynolds LA, Petersen C, et al. Fecal microbiota transplantation from protozoa-exposed donors downregulates immune response in a germ-free mouse model, its role in immune response and physiology of the intestine. PLoS One 2024; 19(10): e0312775.
• 51. Verma AK, Verma R, Ahuja V, Paul J. Real-time analysis of gut flora in Entamoeba histolytica infected patients of Northern India. BMC Microbiology 2012; 12: 183.
• 52. Gilchrist CA, Petri SE, Schneider BN, Reichman DJ, Jiang N, Begum S, et al. Role of the gut microbiota of children in diarrhea due to the protozoan parasite Entamoeba histolytica. Journal of Infectious Diseases 2016;213(10): 1579-85.
• 53. Bartelt LA, Bolick DT, Mayneris-Perxachs J, Kolling GL, Medlock GL, Zaenker EI, et al. Cross-modulation of pathogen-specific pathways enhances malnutrition during enteric co-infection with Giardia lamblia and enteroaggregative Escherichia coli. PLoS Pathogens 2017; 13(7): e1006471.